Independent Drug Value Assessment Act
Summary
Independent Drug Value Assessment Act This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).
Bill status
in committee
1 of 4 stages cleared
Introduction
Nov 2022
Committee Review
Floor Vote
President
Introduced Nov 16, 2022
Last action Nov 17, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Nov 17, 2022
Committee
Referred to the Subcommittee on Health.
lower
Nov 16, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Nov 16, 2022
Introduced
Introduced in House
lower
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Jackie Speier
DDemocratic
Co
Jerrold Nadler
DDemocratic
Co
Katie Porter
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 9321
Scope: US
Hi! I can help you understand HR 9321. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline